In direct compression campaigns for immediate-release oral solid dosage forms, 1-aminohydantoin hydrochloride is first passed through a 500 µm conical screen to disperse agglomerates formed during storage at ambient relative humidity above 60%. The screened API is blended with microcrystalline cellulose PH-102, pregelatinized starch, croscarmellose sodium, colloidal silicon dioxide, and magnesium stearate in a bin blender at 12 rpm for 15 minutes; the lubricant is withheld until the final 3 minutes to avoid hydrophobic film formation on water-soluble particles. The API addition ratio is determined arithmetically by the dose and target tablet mass: a 50 mg dose in a 250 mg tablet corresponds to 20.0% w/w, and a 100 mg dose in the same tablet weight corresponds to 40.0% w/w. These values are not a compendial monograph but are the loading range at which direct compression feasibility is commonly evaluated. Compliance during release testing includes uniformity of dosage units per USP <905> with an acceptance value not exceeding 15.0, dissolution per USP <711> using Apparatus 2 at 50 rpm in 900 mL of 0.1 N hydrochloric acid, elemental impurities per ICH Q3D Option 1, and finished product testing under 21 CFR 211.165 and 211.166. Compression is performed on a rotary tablet press equipped with B-tooling; precompression force is maintained between 2 kN and 4 kN, main compression force is adjusted in the 8–18 kN range, and turret speed is limited to 40–80 rpm until punch sticking or capping data are collected. Tablet hardness is monitored at 60–90 N, and friability is kept below 1.0% w/w. Because the primary amine on the hydantoin ring can react with aldehyde and ketone carbonyls, lactose monohydrate is replaced with mannitol or dibasic calcium phosphate dihydrate after forced degradation screening; this is an operational boundary rather than a blanket excipient ban. Published data for this specific configuration are limited, and the starting compression parameters are derived from general oral solid dose development practice rather than from a finished-product monograph. Terminal product type: immediate-release tablets.

Capsule Filling with Tamping-Pin Dosator Machines and Low-Fill-Weight Variance

In powder-in-capsule production, the direct compression blend is densified to a tapped bulk density of 0.55–0.70 g/mL before transfer to a tamping-pin dosator machine, because low-density powder causes short fill weights and high weight variability on rotary capsule fillers. API addition ratio follows the same arithmetic approach: a 50 mg dose in a size 1 capsule with 250 mg fill weight is 20.0% w/w, and a 100 mg dose in a size 1 capsule with 300 mg fill weight is 33.3% w/w. Particle size is controlled at D90 ≤ 250 µm to reduce dissolution lag; if incoming API lot D50 varies by more than 25% from the reference lot, a 60-mesh sieve analysis is performed before blending. Compliance for release includes weight variation per USP <905>, dissolution per USP <711>, disintegration per USP <701> with an internal limit of 15 minutes for immediate-release capsules, residual solvents per ICH Q3C, and batch testing under 21 CFR 211.165. The capsule filler is operated at 60,000–120,000 capsules/h; dosator pin height is adjusted from 3.0 mm to 4.5 mm to maintain fill weight uniformity. Over-lubrication with magnesium stearate above 1.0% w/w is a known batch-to-batch failure mode because it produces delayed disintegration and variable dissolution; when this occurs, the lubricant is reduced to 0.5% w/w or sodium stearyl fumarate is substituted at 0.5–1.0% w/w. Terminal product type: immediate-release hard gelatin or HPMC capsules.

Where a formulation containing 1-aminohydantoin hydrochloride requires densification because bulk density falls below 0.45 g/mL or the flow function coefficient measured by shear cell is below 4.0, dry granulation is inserted before tablet compression or capsule filling to avoid exposing the water-soluble hydrochloride salt to aqueous binder. In dry granulation, the API addition ratio can be extended into a higher loading range because granule density rather than particle coating is the main mechanism; a 50 mg dose in a 250 mg granule fill weight corresponds to 20.0% w/w, and a 150 mg dose in a 300 mg fill weight corresponds to 50.0% w/w. Ribbon compaction is carried out on a roller compactor with ribbed rolls at 4–8 MPa hydraulic pressure and a roll gap of 1.5–2.5 mm; the resulting ribbons are milled through an oscillating granulator with a 0.8–1.25 mm screen. Overcompaction above 8 MPa reduces granule porosity and slows dissolution, so ribbon solid fraction is monitored by envelope density and kept below 0.75. Compliance includes powder flow testing per USP <1174>, dissolution per USP <711>, uniformity of dosage units per USP <905>, powder fineness per USP <811>, elemental impurities per ICH Q3D, and process validation under 21 CFR 211.110. Extragranular croscarmellose sodium is added at 2.0–4.0% w/w to preserve tablet disintegration after compression, while magnesium stearate is limited to 0.5% w/w to avoid lubricant smearing on the milled granule surfaces. Terminal product type: immediate-release tablets or capsules produced from dry granulated intermediate.

What Process Adjustments Are Required for High-Shear Wet Granulation of a Water-Soluble Hydantoin Salt?

High-shear wet granulation of 1-aminohydantoin hydrochloride presents a dual-phase problem: the hydrochloride salt dissolves rapidly in water, so an aqueous binder can generate localized supersaturation and irregular agglomeration before uniform binder distribution is achieved. The API addition ratio in the finished dried granule is set by the target tablet weight and dose; a 50 mg dose in a 200 mg tablet weight corresponds to 25.0% w/w, and a 100 mg dose in a 250 mg tablet weight corresponds to 40.0% w/w. Polyvinylpyrrolidone K30 is dissolved in purified water and sprayed at 3–5% w/w relative to dry powder during the binder addition phase. Granulation is performed in a high-shear granulator at impeller speed 200–400 rpm and chopper speed 1500–3000 rpm; wet massing is limited to 2–5 minutes because prolonged water contact can produce coarse granules above 1.5 mm and slow dissolution. The wet granules are dried in a fluid-bed dryer at inlet air temperature 50–60°C to a loss-on-drying endpoint of 1.5–2.5% w/w, then milled through a 1.0 mm screen. Compliance testing includes water determination per USP <921>, dissolution per USP <711>, uniformity of dosage units per USP <905>, elemental impurities per ICH Q3D, and in-process sampling under 21 CFR 211.110. If residual moisture exceeds 2.5% w/w after drying, the batch is re-dried before compression because residual water accelerates hydantoin ring hydrolysis under acidic microenvironments. Terminal product type: immediate-release tablets or compression-ready granules.

During fluid-bed top-spray granulation, aqueous binder is sprayed at 8–12 g/min/kg of dry charge onto a fluidized bed of the hydrochloride salt, mannitol, and pregelatinized starch, producing oral granules for single-dose sachets or tablet compression. The API addition ratio is lower in sachet formats because a larger fill weight is required for dose uniformity in stick-pack lines; a 50 mg dose in a 2.0 g sachet corresponds to 2.5% w/w, and a 100 mg dose in a 2.0 g sachet corresponds to 5.0% w/w. Binder solution is delivered with atomization air at 1.8–2.5 bar; inlet air temperature is 55–70°C, product temperature is kept at 28–32°C, and drying continues to a loss-on-drying endpoint of 1.0–2.0% w/w. The granulated material is sieved through a 1.25 mm screen and blended with 0.2–0.5% w/w colloidal silicon dioxide to improve flow into stick-pack filling stations. Compliance includes powder flow testing per USP <1174>, particle size distribution per USP <811>, moisture per USP <921>, dissolution per USP <711> where a tablet claim is pursued, uniformity of dosage units per USP <905> for finished sachets, and release testing under 21 CFR 211.165. Product temperature above 40°C is avoided as a conservative boundary; published data for the thermal stability of this specific hydantoin salt in a fluid-bed environment are limited. Terminal product type: oral granules in sachets or tablets after final blending.

When Terminal Sterilization Is Applied to Aqueous Injectable Solutions Containing 1-Aminohydantoin Hydrochloride

Aqueous injectable solutions are compounded in Water for Injection at 4–8°C under nitrogen sparging because the primary amine in the hydantoin ring can participate in oxidative side reactions with dissolved oxygen. The API concentration in the finished solution is expressed as weight per volume: a 10 mg/mL product corresponds to 1.0% w/v; a 1 mg/mL product corresponds to 0.1% w/v; concentrated formulations above 10.0% w/v are evaluated separately because viscosity and osmolality changes alter filter throughput. The solution is pH-adjusted with diluted hydrochloric acid or sodium hydroxide, then passed through a 0.22 µm polyethersulfone filter and filled into Type I borosilicate glass vials or ampoules. Terminal sterilization may be performed at 121°C for 15 minutes with an accumulated F₀ not less than 8 minutes, but only after thermal stability screening demonstrates that the hydantoin ring remains intact; if not, aseptic filtration without terminal sterilization is required. Compliance includes sterility per USP <71>, bacterial endotoxins per USP <85> using a limit calculated from the maximum bolus dose, particulate matter per USP <788> with small-volume parenteral limits of not more than 6000 particles ≥ 10 µm and 600 particles ≥ 25 µm per container, visible particulates per USP <790>, elemental impurities per ICH Q3D, and current good manufacturing practice under 21 CFR 210 and 211. Production-scale failure mode: autoclave load cold spots may produce an F₀ distribution with a minimum below 8 minutes; process validation therefore uses biological indicators placed in the slowest-heating container location. Terminal product type: aqueous injectable solution in vials or ampoules.

Lyophilized injection batches are compounded in Water for Injection at 4–8°C, filtered through a 0.22 µm sterile filter, and filled into Type I glass vials before freeze-drying; mannitol or glycine is added as a bulking agent to prevent cake collapse and support mechanical strength during transport. The API addition ratio is expressed as weight per volume of the pre-lyophilization solution: a 10 mg/mL product contains 1.0% w/v 1-aminohydantoin hydrochloride, while mannitol is added at 4–8% w/v depending on the collapse temperature measured by freeze-dry microscopy. The lyophilization cycle uses a shelf ramp to -40°C at 0.5–1.0°C/min and a freezing hold of 2–4 hours; primary drying is carried out at shelf temperature -25°C to -20°C and chamber pressure 100–200 mTorr until the product temperature approaches shelf temperature, typically 24–48 hours. Secondary drying is performed at 25–30°C for 4–8 hours to a moisture endpoint below 1.0% w/w. Compliance includes moisture determination per USP <921>, sterility per USP <71>, bacterial endotoxins per USP <85>, particulate matter per USP <788>, container closure integrity per USP <1207>, elemental impurities per ICH Q3D, and finished product testing under 21 CFR 211.165. If freeze-dry microscopy data are unavailable for a new formulation, the primary drying shelf temperature is held at -25°C as a conservative operational boundary to avoid cake collapse. Terminal product type: lyophilized cake for reconstitution before parenteral administration.